| Original language | English |
|---|---|
| Article number | 1901681 |
| Journal | European Respiratory Journal |
| Volume | 55 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2020 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. / Alfieri, Veronica; Crisafulli, Ernesto; Visca, Dina; Chong, Wing Ho; Stock, Carmel; Mori, Letizia; de Lauretis, Angelo; Tsipouri, Vicky; Chua, Felix; Kouranos, Vasilis; Kokosi, Maria; Hogben, Charlotte; Molyneaux, Philip L.; George, Peter M.; Maher, Toby M.; Chetta, Alfredo A.; Sestini, Piersante; Wells, Athol U.; Renzoni, Elisabetta A.
In: European Respiratory Journal, Vol. 55, No. 2, 1901681, 01.02.2020.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease
AU - Alfieri, Veronica
AU - Crisafulli, Ernesto
AU - Visca, Dina
AU - Chong, Wing Ho
AU - Stock, Carmel
AU - Mori, Letizia
AU - de Lauretis, Angelo
AU - Tsipouri, Vicky
AU - Chua, Felix
AU - Kouranos, Vasilis
AU - Kokosi, Maria
AU - Hogben, Charlotte
AU - Molyneaux, Philip L.
AU - George, Peter M.
AU - Maher, Toby M.
AU - Chetta, Alfredo A.
AU - Sestini, Piersante
AU - Wells, Athol U.
AU - Renzoni, Elisabetta A.
N1 - Funding Information: Conflict of interest: V. Alfieri has nothing to disclose. E. Crisafulli has nothing to disclose. D. Visca has nothing to disclose. W.H. Chong has nothing to disclose. C. Stock has nothing to disclose. L. Mori has nothing to disclose. A. de Lauretis has nothing to disclose. V. Tsipouri has nothing to disclose. F. Chua reports lecture fees and advisory board fees from Boehringer Ingelheim and from Roche, outside the submitted work. V. Kouranos has nothing to disclose. M. Kokosi has nothing to disclose. C. Hogben has nothing to disclose. P.L. Molyneaux has, via his institution, received industry-academic funding from Roche, Boehringer Ingelheim and Galapagos and has received speaker fees from Roche. P.M. George reports grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche, personal fees from Teva, outside the submitted work. T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speaker fees from Apellis, AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, GlaxoSmithKline R&D, Indalo, Novartis, Pliant, ProMetic, Respivnat, Roche, Samumed and UCB. A.A. Chetta has nothing to disclose. P. Sestini has nothing to disclose. A.U. Wells reports lecture fees and advisory board fees from Boeringher Ingelheim, Roche and Bayer, outside the submitted work. E.A. Renzoni reports lecture fees and advisory board fees from Boeringher Ingelheim and Roche, and lecture fees from Mundipharma, outside the submitted work. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/1
Y1 - 2020/2/1
UR - http://www.scopus.com/inward/record.url?scp=85081144837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081144837&partnerID=8YFLogxK
U2 - 10.1183/13993003.01681-2019
DO - 10.1183/13993003.01681-2019
M3 - Letter
C2 - 31699833
AN - SCOPUS:85081144837
VL - 55
JO - European Respiratory Journal
JF - European Respiratory Journal
SN - 0903-1936
IS - 2
M1 - 1901681
ER -